References
- Nygren P. What is cancer chemotherapy?. Acta Oncol 2001; 40: 166–74
- Sandström M, Freijs A, Larsson R, et al. Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin and 4-hydroxocyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581–8
- Bremberg ER, Rotstein S, Eksborg S. Treatment modifications of antineoplastic drugs in an oncology day-care unit. Acta Oncol 2007 ( in press).
- Bremberg ER, Hising C, Nylén U, et al. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract 2006; 12: 75–81
- Sandström M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006; 58: 143–56